The high cost of sickle cell gene therapies is pushing private insurers and Medicaid programs to develop new payment models.

The additive manufacturing sector continues to show near-limitless potential. Innovations have taken 3D printers from creating customized figurines all the way to printing entire neighborhoods, ...

U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated ...

Vertex Pharmaceuticals VRTX has outperformed the market over the past 15 years by 5.86% on an annualized basis producing an average annual return of 17.7%. Currently, Vertex Pharmaceuticals has a ...

At a time when many life sciences companies are shrinking their workforce, Vertex Pharmaceuticals Inc. has once again grown ...

We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...

25 analysts have shared their evaluations of Vertex Pharmaceuticals (NASDAQ:VRTX) during the recent three months, expressing a mix of bullish and bearish perspectives. The following table ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) was downgraded by research analysts at StockNews.com from a “buy” rating to a “hold” rating in a report released on Wednesday.

Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

With a market cap of $118.7 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a global biotechnology leader specializing in the development of innovative therapies for serious diseases.

In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other Renaissance Technologies portfolio’s top stock picks. The American ...

Here's why they picked AstraZeneca (NASDAQ: AZN), Eli Lilly (NYSE: LLY), and Vertex Pharmaceuticals (NASDAQ: VRTX). Here's why they think Eli Lilly (NYSE: LLY), Summit Therapeutics (NASDAQ ...